Annual CFO
-$124.51 M
-$54.45 M-77.71%
31 December 2023
Summary:
Keros Therapeutics annual cash flow from operations is currently -$124.51 million, with the most recent change of -$54.45 million (-77.71%) on 31 December 2023. During the last 3 years, it has fallen by -$87.61 million (-237.47%). KROS annual CFO is now -1868.08% below its all-time high of $7.04 million, reached on 31 December 2018.KROS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$30.50 M
+$9.30 M+23.37%
30 September 2024
Summary:
Keros Therapeutics quarterly cash flow from operations is currently -$30.50 million, with the most recent change of +$9.30 million (+23.37%) on 30 September 2024. Over the past year, it has increased by +$3.48 million (+10.25%). KROS quarterly CFO is now -2037.35% below its all-time high of -$1.43 million, reached on 31 March 2022.KROS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$140.32 M
+$3.48 M+2.42%
30 September 2024
Summary:
Keros Therapeutics TTM cash flow from operations is currently -$140.32 million, with the most recent change of +$3.48 million (+2.42%) on 30 September 2024. Over the past year, it has dropped by -$19.83 million (-16.46%). KROS TTM CFO is now -5483.76% below its all-time high of -$2.51 million, reached on 31 March 2019.KROS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KROS Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -77.7% | +10.3% | -16.5% |
| 3 y3 years | -237.5% | -111.2% | -177.4% |
| 5 y5 years | -1868.1% | -932.1% | -1236.4% |
KROS Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -237.5% | at low | -2037.3% | +31.6% | -177.4% | +2.4% |
| 5 y | 5 years | -1868.1% | at low | -2037.3% | +31.6% | -1236.4% | +2.4% |
| alltime | all time | -1868.1% | at low | -2037.3% | +31.6% | -5483.8% | +2.4% |
Keros Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$30.50 M(-23.4%) | -$140.32 M(-2.4%) |
| June 2024 | - | -$39.80 M(-10.7%) | -$143.80 M(+6.7%) |
| Mar 2024 | - | -$44.56 M(+75.0%) | -$134.83 M(+8.3%) |
| Dec 2023 | -$124.51 M(+77.7%) | -$25.46 M(-25.1%) | -$124.51 M(+3.3%) |
| Sept 2023 | - | -$33.98 M(+10.2%) | -$120.49 M(+8.4%) |
| June 2023 | - | -$30.83 M(-9.9%) | -$111.11 M(+8.0%) |
| Mar 2023 | - | -$34.23 M(+59.7%) | -$102.87 M(+46.8%) |
| Dec 2022 | -$70.06 M(+12.7%) | -$21.44 M(-12.8%) | -$70.06 M(+2.8%) |
| Sept 2022 | - | -$24.60 M(+8.9%) | -$68.18 M(+17.5%) |
| June 2022 | - | -$22.59 M(+1483.0%) | -$58.02 M(+9.3%) |
| Mar 2022 | - | -$1.43 M(-92.7%) | -$53.07 M(-14.6%) |
| Dec 2021 | -$62.15 M | -$19.57 M(+35.5%) | -$62.15 M(+22.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$14.44 M(-18.1%) | -$50.57 M(+7.6%) |
| June 2021 | - | -$17.64 M(+67.9%) | -$46.99 M(+19.6%) |
| Mar 2021 | - | -$10.51 M(+31.5%) | -$39.28 M(+6.5%) |
| Dec 2020 | -$36.89 M(+130.6%) | -$7.99 M(-26.4%) | -$36.89 M(+7.2%) |
| Sept 2020 | - | -$10.86 M(+9.4%) | -$34.40 M(+29.8%) |
| June 2020 | - | -$9.93 M(+22.3%) | -$26.50 M(+22.7%) |
| Mar 2020 | - | -$8.12 M(+47.7%) | -$21.61 M(+35.0%) |
| Dec 2019 | -$16.00 M(-327.2%) | -$5.50 M(+86.1%) | -$16.00 M(+52.4%) |
| Sept 2019 | - | -$2.96 M(-41.3%) | -$10.50 M(+39.2%) |
| June 2019 | - | -$5.03 M(+100.2%) | -$7.54 M(+200.2%) |
| Mar 2019 | - | -$2.51 M | -$2.51 M |
| Dec 2018 | $7.04 M | - | - |
FAQ
- What is Keros Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Keros Therapeutics?
- What is Keros Therapeutics annual CFO year-on-year change?
- What is Keros Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Keros Therapeutics?
- What is Keros Therapeutics quarterly CFO year-on-year change?
- What is Keros Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Keros Therapeutics?
- What is Keros Therapeutics TTM CFO year-on-year change?
What is Keros Therapeutics annual cash flow from operations?
The current annual CFO of KROS is -$124.51 M
What is the all time high annual CFO for Keros Therapeutics?
Keros Therapeutics all-time high annual cash flow from operations is $7.04 M
What is Keros Therapeutics annual CFO year-on-year change?
Over the past year, KROS annual cash flow from operations has changed by -$54.45 M (-77.71%)
What is Keros Therapeutics quarterly cash flow from operations?
The current quarterly CFO of KROS is -$30.50 M
What is the all time high quarterly CFO for Keros Therapeutics?
Keros Therapeutics all-time high quarterly cash flow from operations is -$1.43 M
What is Keros Therapeutics quarterly CFO year-on-year change?
Over the past year, KROS quarterly cash flow from operations has changed by +$3.48 M (+10.25%)
What is Keros Therapeutics TTM cash flow from operations?
The current TTM CFO of KROS is -$140.32 M
What is the all time high TTM CFO for Keros Therapeutics?
Keros Therapeutics all-time high TTM cash flow from operations is -$2.51 M
What is Keros Therapeutics TTM CFO year-on-year change?
Over the past year, KROS TTM cash flow from operations has changed by -$19.83 M (-16.46%)